Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司产品终止注册的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the termination of registration of a product by its wholly-owned subsidiary. It details regulatory decisions by the National Medical Products Administration (NMPA) about a medical device registration application being denied. The document includes background on the product, reasons for non-registration, and the impact on the company. It is a regulatory announcement about a product registration status, not a financial report, earnings release, or management discussion. The document length is short (1473 characters) and it is a formal announcement of a regulatory decision. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-20 Chinese
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain fundraising special accounts related to the company's previously raised funds. It details the background of the fundraising, the management and use of the funds, and the specific accounts being closed with remaining balances transferred. There is no financial statement, comprehensive financial data, or detailed report content. The document is relatively short (3432 characters) and serves as a formal notification about the status of fundraising accounts and related administrative actions. This fits the category of a Capital/Financing Update (CAP) as it relates to the management and changes in the company's fundraising capital accounts rather than a full financial report or audit.
2024-05-14 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二三年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of the 2023 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but focuses on the legal compliance of the AGM process and voting outcomes. The document length is 8066 characters, which is substantial but the content is clearly a legal opinion on the AGM proceedings rather than the AGM materials themselves. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, or related legal opinions about the AGM. Since this is a legal opinion letter specifically about the AGM, it is best classified as AGM Information (AGM-R).
2024-05-09 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for Shenzhen BGI Genomics Co., Ltd. It details the date, time, and method of the AGM, attendance statistics, and the voting results on various proposals including the 2023 annual report, board and supervisory reports, financial statements, profit distribution plan, auditor appointment, credit facility applications, asset impairment provisions, and amendments to the auditor selection system. It also includes legal opinions confirming the legality of the meeting and voting procedures. The document is essentially an official announcement of the resolutions passed at the AGM, including voting results, rather than the full annual report or financial statements themselves. The length is about 5,067 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-09 Chinese
关于召开2023年年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement about the convening of the 2023 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, agenda items including approval of the 2023 annual report, board and supervisory reports, financial statements, profit distribution plan, and other proposals. It also contains instructions for shareholder registration and proxy voting. The document does not contain the actual annual report or financial statements but rather serves as a notice and procedural guide for the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length (5525 characters) and content confirm it is not a brief announcement or a report publication notice but a full AGM notice with detailed procedural information.
2024-05-06 Chinese
上海信公轶禾企业管理咨询有限公司关于深圳华大基因股份有限公司2022年限制性股票激励计划首次授予部分第一期归属相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the "2022 Restricted Stock Incentive Plan" of Shenzhen BGI Genomics Co., Ltd. It discusses the approval procedures, conditions for stock vesting, adjustments in grant price, and the number of shares vested. The document is detailed, contains financial and procedural information about a stock incentive plan, and is issued by an independent financial advisor. It is not an annual or quarterly report, earnings release, or a general announcement. It is a specialized report related to stock incentive plans and their vesting conditions, which aligns with the category of Audit Report / Information (AR) as it involves independent verification and opinion on a specific financial matter related to stock incentives. The document is not a mere announcement or a proxy solicitation, but a full report with detailed analysis and opinions. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2023
2024-04-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.